Clinical trial
A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer…
NCT00091663 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00091663 |
|---|---|
| Title | A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Official title | A Multicenter, Open-Label, Phase IIIb Trial of Tarceva (Erlotinib Hydrochloride) in Patients With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Cancer, Non-small-cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | Tarceva (erlotinib HCl) |
| Enrollment | 5,000 |
| Start date | Aug 1, 2004 |
| Completion | Aug 1, 2005 |
| First posted | Sep 16, 2004 |
| Last update posted | Mar 4, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: